Jiangsu Hengrui Medicine
600276.SS
#494
Rank
HK$314.21 B
Marketcap
HK$49.26
Share price
-0.62%
Change (1 day)
1.08%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): HK$6.47 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are HK$3.63 Billion. In 2023 the company made an earning of HK$5.12 Billion, an increase over its 2022 earnings that were of HK$4.60 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) HK$6.47 B26.31%
2023 HK$5.12 B11.4%
2022 HK$4.60 B-13.65%
2021 HK$5.32 B-34.21%
2020 HK$8.10 B15.95%
2019 HK$6.98 B33.03%
2018 HK$5.25 B20.89%
2017 HK$4.34 B23.89%
2016 HK$3.50 B11.21%
2015 HK$3.15 B39.5%
2014 HK$2.26 B20.61%
2013 HK$1.87 B11.46%
2012 HK$1.68 B29.7%
2011 HK$1.29 B31.16%
2010 HK$0.98 B27.92%
2009 HK$0.77 B5.8%
2008 HK$0.73 B79.95%
2007 HK$0.40 B32.89%
2006 HK$0.30 B38.19%
2005 HK$0.22 B21.56%
2004 HK$0.18 B13.95%
2003 HK$0.15 B38.06%
2002 HK$0.11 B